CDC advisory panel debates next steps with Johnson & Johnson vaccine, makes no recommendation yet
CDC advisors are deciding how to move forward after recommending a pause on J&J vaccines.
and last updated 2021-04-14 19:04:25-04
A CDC advisory panel debated possible next steps in the administration of the Johnson & Johnson COVID-19 vaccine, and after hours of questions and presentations, decided Wednesday they wanted more information about the rare instances of blood clots to make a recommendation.
The Advisory Committee on Immunization Practices (ACIP) held an emergency meeting Wednesday afternoon to review what is known about the six reported U.S. cases of a rare and severe type of blood clot in people after getting the J&J vaccine. As of Monday, nearly seven million doses of the J&J vaccine had been administered in the U.S.